|
|
|
|
|
|
by blub
27 days ago
|
|
|
It’s trivial to publish these so that they’re both easily available and easy to understand. I’m guessing that’s not the case for the CDC, since you didn’t post any link or guideline. A nice example was the EUCDC guidance on AstraZeneca’s vaccine which showed that for young age groups the vaccine was more dangerous than the disease. That allows anyone to make an informed decision for themselves instead of being bullied or emotionally blackmailed “for the greater good”. Par for the course, I can’t access the actual study from The Lancet and have to settle for second-rate journalist summaries which are typically biased and ultimately worthless. |
|
|
Here's a step by step guide for you:
1. Google "Pfizer covid vaccine studies CDC"
2. Click top result: https://www.cdc.gov/acip/grade/covid-19-pfizer-biontech-vacc...
3. Scroll to results:
> Outcomes of interest included individual benefits and harms. Indirect effects of vaccination (e.g., societal benefits) were not considered...
> In the Phase II/III RCT, using data on all blinded follow-up (up to 6 months or the unblinding date of March 13, 2021), the Pfizer-BioNTech COVID-19 vaccine reduced symptomatic COVID-19 when compared to placebo (vaccine efficacy: 91.1% (95% CI 88.8–93.1%)) (Table 3a). For hospitalization due to COVID-19, 31 events occurred, all in the placebo group. Vaccine efficacy against hospitalization due to COVID-19 was 100% (95% CI 87.6–100%) (Table 3b). Deaths due to COVID-19 were uncommon, one in the vaccine group and six in the placebo group (83% (-39–98%)) (Table 3c). Numbers of SAEs were comparable between the vaccine group and the placebo group across the two RCTs (Phase II/III: 268/21,926 (1.2%) vs. 268/21,921 (1.2%); Phase I: 1/24 (4.2%) vs. 0/6 (0.0%)); there were no cases of vaccine-associated enhanced disease or vaccine-related deaths (Table 3e). Grade ≥3 reactions generally were not uncommon and occurred more frequently in the vaccine than placebo groups (Table 3f).